Patient Engagement: We are leveraging the Eureka platform to create an interface for patient participants in the prospective component of HeartShare that allows eConsents and completion of forms and that facilitates communication with participants; collects mobile health (mHealth) data from home devices, sensors, and mobile apps; and seamlessly integrate with other data sources in BioData Catalyst. Eureka will allow HeartShare patients to engage in all phenotyping protocols. The Eureka platform, developed at UCSF with NIH-funding (U2CEB021881), is a direct-to-participant digital platform as a resource for enabling efficient mHealth research. Detailed information about the Eureka Research Platform can be found at https://info.eurekaplatform.org. Building upon experience and technology developed by the UCSF team for the Health eHeart Study, >55 individual research studies have been launched on the Eureka platform, engaging over 500,000 participants and led by researchers at multiple institutions across multiple disease areas. The Eureka Platform, which is available on the web and Eureka’s native mobile apps (iOS and Android), is designed for scalability, cost-effectiveness and speed of study startup. The platform is architected with a robust backend that can host numerous studies, each with its own unique look and feel, study design, study activities and flow (Eureka Platform in HeartShare Figure). The backend dynamically delivers content to a Eureka mobile app and/or web-based interface. The Eureka architecture will allow for the rapid (and very cost-efficient) development of a HeartShare mHealth tracking and patient engagement resource without the need to develop a new app de novo. Eureka can be developed and deployed in 3-6 weeks. Eureka is a custom-built, HIPAA-compliant platform that runs on AWS, allowing scalability, and provides for redundancy, security, and data integrity. While Eureka is optimized for remote study participation, it is also equipped for in-person studies and hybrid studies with both remote and in-person components. Built as a national collaborative resource for mHealth research, Eureka is currently used for projects funded by NIH, PCORI, industry and others, including several large multi-center studies. The table below displays the many functions provided by the Eureka platform, which are relevant to HeartShare.  

For HeartShare participants who do not have access to internet or technology, and therefore cannot use the Eureka web- or smartphone-based apps, we will follow the ADAPTABLE clinical trial protocol and offer a non-internet enrollment pathway and survey completion via HeartShare Clinical Center staff or the DTC call center staff, which will involve telephone follow-up with study coordinator data entry into Eureka directly.

Patient Experience: Interested participants, patients with heart failure with preserved ejection fraction (HFpEF) and comparators without HFpEF, will be invited to sign up for Eureka on the iOS or Android mobile app or on the study website.  They will create an account with an embedded Unique Participant Code that will be linked the patient’s MRN.  Upon account creation, they will be presented with an eligibility survey, and eligible participants will be prompted to sign the study eConsent. The Eureka platform will deliver surveys to the participant on a predetermined cadence.  Each “batch” of surveys is called an eVisit, and these eVisits will be open for one month (except the baseline eVisit which will be open for 3 months).

The Eureka platform will send regular reminders via Push Messages, SMS Messages, and emails to remind participants of their incomplete surveys.  Once eVisit surveys are completed, the participant will no longer receive reminders until their next eVisit opens.